Also, if I may add, Prometic is a 2 segment business at this point, with the fractionation starting to make it's place in the market, and the therapeutic unit, still trying to come to life. There is potential, which may be huge, in the therapeutic business, but also a segment requiring much more capital if someone wants to grab it and run with it. A possible suitor will not want to acquire PLI until the therapeutic is showing some positive data down the road, after the basic work has been done with a partner to take it there. What I'm saying is that PLI isn't matured enough for someone to take it over at this point, but like francois says, once the revenues show sighns of growth and the company is taking bites at the existing market, they will start to attract attention from the bigger players.

$3/share takeover sounds good to me